微芯生物是由资深留美归国博士团队于2001年3月创立的中国原创新药领域的先行者。公司秉承“原创、优效、安全、中国”的理念，专注对人类生命健康造成严重威胁的恶性肿瘤、代谢性疾病、自身免疫性疾病、中枢神经系统疾病及抗病毒等五大领域的原创新药研发，致力于为患者提供可承受的、临床亟需的、具有革命性疗效的创新机制药物。微芯生物是科创板首家过会企业及第一家上市的生物医药企业（股票代码688321.SH）。
Location: China, Guangdong Province, Shenzhen
Employees: 51-200
Investors 2
| Date | Name | Website |
| - | LAV | lavfund.co... |
| - | Cowin Capi... | cowincapit... |
Mentions in press and media 11
| Date | Title | Description |
| 31.07.2025 | Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development | SHENZHEN, China, July 31, 2025 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. ("Chipscreen Biosciences") announced that its wholly owned subsidiary, Chipscreen Biosciences (USA) Ltd., has received Investigational New Dr... |
| 17.07.2025 | Sino Biopharm to Buy Out LaNova for Up to USD951 Million, Heralding Potential M&A Wave | (Yicai) July 17 -- Sino Biopharmaceutical said it plans to spend as much as USD951 million to fully acquire LaNova Medicines, a move that may point to more mergers and acquisitions in the Chinese drugs industry. Sino Biopharm will buy the 9... |
| 24.03.2025 | China’s biotech sector is undervalued given its AI-driven opportunities: Investor | - |
| 01.11.2024 | The Phase III clinical trial application for first-line treatment of extensive disease small cell lung cancer with Chiauranib has been approved | SHENZHEN, China, Nov. 1, 2024 /PRNewswire/ -- On November 1, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceutical Ltd., r... |
| 18.10.2024 | Chipscreen Biosciences: Pioneering New Frontiers in Liver and Cancer Treatments | In the realm of pharmaceuticals, innovation is the lifeblood. Chipscreen Biosciences, a trailblazer in drug development, is making waves with two promising candidates: Chiglitazar for metabolic associated steatohepatitis (MASH) and CS231295... |
| 17.10.2024 | Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets: Investigational New Drug (IND) Application Accepted | SHENZHEN, China, Oct. 17, 2024 /PRNewswire/ -- On October 17, 2024, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) submitted the company's Investigational New Drug (IND) application for CS231295 ... |
| 15.10.2024 | Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting | SHENZHEN, China, Oct. 15, 2024 /PRNewswire/ -- On October 15, 2024, the list of selected candidates for the oral report of the American Association for the Study of the Liver (AASLD 2024) annual meeting was officially announced online. The ... |
| 19.07.2024 | Treatment of Type 2 diabetes with Chiglitazar combined with Metformin Approved for listing by the National Medical Products Administration | SHENZHEN, China, July 19, 2024 /PRNewswire/ -- On July 19, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") announced that it has received the Drug Registration Certificate approved a... |
| 30.04.2024 | National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma | SHENZHEN, China, April 30, 2024 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative product Chidamide (Epidaza®) , an oral subtype-selectiv... |
| 19.10.2021 | Chipscreen Biosciences Announces NMPA New Drug Approval of Bilessglu® (Chiglitazar Sodium tablets) for ( Type 2 Diabetes) in China | SHENZHEN, China, Oct. 19, 2021 /PRNewswire/ -- SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (hereinafter referred to as: CHIPSCREEN), a China headquartered biopharmaceutical company developing and marketing novel drugs based on its unique tech... |
Show more